Divergent roles of nitrergic and prostanoid pathways in chronic joint inflammation

Annals of the Rheumatic Diseases

Volumn 63, Issue 12, 2004, Pages 1564-1570

  Day, S M ^a   Lockhart, J C ^a   Ferrell, W R ^b   McLean, J S ^a  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CARRAGEENAN; FREUND ADJUVANT; KAOLIN; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN E2; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC ARTHRITIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG POTENTIATION; HISTOPATHOLOGY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; RAT; URINE LEVEL;

ACUTE DISEASE; ANIMALS; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CHRONIC DISEASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENZYME INHIBITORS; ISOENZYMES; LYSINE; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES;

EID: 9644260610     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.017269     Document Type: Article

References (43)

1. Coleman JW. Review: Nitric oxide in immunity and inflammation. Int Immunopharmacol 2001;1:1397-406.
2. Prete PE, Gurakar-Osborne A. The contribution of synovial fluid lipoproteins in the chronic synovitis of rheumatoid arthritis. Prostaglandins 1997;54:689-98.
3. Day SM, McLean JS, Lockhart JC, Ferrell WR. Combined inhibition of nitrergic and prostanoid pathways in J774 macrophages. Clin Exp Rheumatol 2003;21:625-31.
4. Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumotol 1996;23:230-6.
5. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 1994;37:1062-9.
6. Bingham CO 3rd. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl 2002;65:3-9.
7. McInnes IB, Leung B, Field M, Wei X-Q, Huang F-P, Sturrock RD, et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteroarthritis patients. J Exp Med 1996;184:1519-24.
8. Sakurai H, Kohsaka H, Liu M-F, Higashiyama H, Hirata Y, Kanno K, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995;96:2357-63.
9. McCartney-Francis NL, Allen JB, Mizel DE, Albina JE, Xie Q-W, Nathan CF, et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993;178:749-54.
10. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995;273:15-24.
11. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH. Comparison of the nitric oxide synthase inhibitors, methylarginine and aminoguanicline as prophylactic and therapeutic agents in rat adjuvant arthritis. J Rheumatol 1995;22:1922-8.
12. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth MA, Gimbrone MA, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
13. Cepinskas G, Lush CW, Kvietys PR. Anoxia/reaxygenation-induced tolerance with respect to polymorphonuclear leukocyte adhesion to cultured endothelial cells. A nuclear factor-kappa B-mediated phenomenon. Circ Res 1999;84:103-12.
14. Khan BV, Harrison DT, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell wall adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996;93:9114-19.
15. Stoclet JC, Muller B, Andriantsitohaina R, Kleschyov A. Overexpression of nitric oxide in pathophysiology of blood vessels. Biochemistry (Mosc) 1998;63:826-32.
16. Stefanovic-Racic M, Morales TI, Taskiran D, McIntyre LA, Evans CH. The role of nitric oxide in proteoglycan turnover by bovine articular cartilage organ cultures. J Immunol 1996;156:1213-20.
17. Stefanovic-Racic M, Mollers MO, Miller LA, Evans CH. Nitric oxide and proteoglycan turnover in rabbit articular cartilage. J Orthop Res 1997;15:442-9.
18. Emery P. Review: Clinical implications of selective cyclooxygenase-2 inhibition. Scand J Rheumatol Suppl 1996;102:23-8.
19. Davies P, MacIntyre DE. Prostaglandins and inflammation. In: Gallin JJ, Goldstein IM, Snyderman R, eds. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992:123-37.
20. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
21. Crofford LJ, Wilder RL, Ristimaki AP, Sana H, Remmers EF, Epps HR, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1 β, phorbol ester and corticosteroids. J Clin Invest 1994;93:1095-101.
22. Corbett JA, Kwon G, Turk J, McDaniel ML. IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide, Biochemistry 1993;32:13767-70.
23. 2alpha production and the nitridergic system during embryonic implantation in the rat. Prostaglandins 1996;51:363-76.
24. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993;90:7240-4.
25. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol 1995;114:1171-8.
26. Stadler J, Harbrecht BG, Di Silvio M, Curran RD, Jordan ML, Simmons RL, et al. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukocyte Biol 1993;53:165-72.
27. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol 1995;114:1335-42.
28. 2 negatively modulates induction of nitric oxide synthase by interleukin 1. Proc Natl Acad Sci USA 1996;91:12168-72.
29. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, et al. Essential role for proteinase-2 activated receptor-2 in arthritis. J Clin Invest 2003;111:35-41.
30. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K. A single amino acid difference between cyclooxygenase -1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996;271:15810-14.
31. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615.
32. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Review: Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
33. van Eden W, Waksman BH. Immune regulation in adjuvant-induced arthritis. Arthritis Rheum 2003;48:1788-96.
34. Cicala C, Ianaro A, Fiorucci S, Calignano A, Bucci M, Gerli R, et al. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol 2000;130:1399-405.
35. Hood VC, Cruwys SC, Urban L, Kidd BL. The neurogenic contribution to synovial leucocyte infiltration and outer outcome measures in a guinea pig model of arthritis. Neurosci Lett 2001;299:201-4.
36. Egan CG, Lockhart JC, Ferrell WR, Day SM, McLean JS. Pathophysiological basis of acute inflammatory hyperaemia in the rat knee: roles of cyclooxygenase-1 and -2. J Physiol 2002;539:579-89.
37. McInnes IB, Leung B, Wei XQ, Gemmell CC, Liew FY. Septic arthritis following Staphylococcus aureus infection in mice lacking inducible nitric oxide synthase. J Immunol 1998;160:308-15.
38. Veihelmann A, Landes J, Hofbauer A, Dorger M, Refior HJ, Messmer K, et al. Exacerbation of antigen-induced arthritis in inducible nitric oxide synthase-deficient mice. Arthritis Rheum 2001;44:1420-7.
39. McCartney-Francis NL, Song XY, Mizel DE, Wahl SM. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease. J Immunol 2001;166:2734-40.
40. Veihelmann A, Hofbauer A, Krombach F, Dorger M, Maier M, Refior HJ, et al. Differential function of nitric oxide in murine antigen-induced arthritis. Rheumatology (Oxford) 2002;41:509-17.
41. Al-Swayeh OA, Clifford RH, del Soldato P, Moore PK. A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br J Pharmacol 2000;129:343-50.
42. Paul-Clark M, Del Soldato P, Fiorucci S, Flower RJ, Perretti M. 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol 2000;131:1345-54.
43. Colville-Nash PR, Willoughby DA. COX-1, COX-2 and articular joint disease: a role for chondroprotective agents. Biorheology 2002;39:171-9.